reports
Hybridan Small Cap Feast - 14 Dec 23
14th December 2023 Small Cap Team will take a break until Monday 8 January 2024 after this Friday 15th December. Merry Christmas to all our readers. @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be...
Artificial intelligence in UK biopharma and healthcare 11/09/2023
Artificial intelligence (AI) continues to accelerate at full speed, first by imitating the workings of a human brain and now it is drawing concepts of evolution, sometimes with synthetic data, artificially manufactured for training purposes or for privacy protection, and sometimes not even with human intervention. In this note, we examine how AI is being developed and applied by the NHS and UK mid/small cap companies for the benefit of human health and wellbeing. AI in drug discovery and devel...
C4X Discovery Holdings plc: Half-year results for the six months ended...
C4X Discovery Holdings plc: Half-year results for the six months ended 31 January 2023 This announcement contains inside information C4X Discovery Holdings plc("C4XD", "C4X Discovery" or the "Company") Half-year results for the six months ended 31 January 2023 Up to $402 million AstraZeneca deal for NRF2 Activator programme; Third global out-licensing deal executed Future strategic focus to deliver high value small molecules to treat immuno-inflammatory diseases Launched PatientSeek, a Precision Medicine platform for optimised patient selection based on its Taxonomy3® genetic analysis ...
C4XD and Garvan Institute of Medical Research report successful patien...
C4XD and Garvan Institute of Medical Research report successful patient stratification approach using C4XD's new precision medicine platform PatientSeek First validation of C4XD's patient sub-groups through a Garvan-led retrospective clinical trial analysis Promising initial result paves way for novel approaches in Parkinson's disease stratification Launch of PatientSeek platform enables stratification of patients to identify the right patient for the right medicine MANCHESTER, United Kingdom, Feb. 22, 2023 (GLOBE NEWSWIRE) -- C4X Discovery Holdings plc (AIM: C4XD), a pione...
EQS-News: C4X Discovery signs potential $402mln deal
EQS-News: C4X Discovery Holdings PLC C4X Discovery signs potential $402mln deal 28.11.2022 / 15:30 CET/CEST The issuer is solely responsible for the content of this announcement. Contact DetailsProactiveProactive UK Ltd 3News Source: News Direct 28.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at -news.com Language: English Com...
C4X Discovery Holdings plc: C4XD signs exclusive global licence worth ...
C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca for the development and commercialisation of NRF2 Activator programme C4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and commercial milestones, and tiered mid-single digit royalties Agreement further substantiates C4XD's scientific expertise and strategy through a third significant deal with a major pharmaceutical company MANCHESTER, United Kingdom, Nov. 28, 2022 (GLOBE NEWSWIRE) -- C4X Discovery Holdings plc (AIM: C4XD), a pioneerin...
Up to €414 million Exclusive Worldwide Licensing Agreement with Sanofi...
Up to €414 million Exclusive Worldwide Licensing Agreement with Sanofi for C4XD oral IL-17A inhibitor programme C4X Discovery Holdings plc Up to €414 million Exclusive Worldwide Licensing Agreement with Sanofi for C4XD oral IL-17A inhibitor programme €7 million upfront payment in addition to potential pre-clinical milestones of €11 million, clinical and commercial milestones plus royalties Second major licensing deal with a global pharmaceutical company in commercially attractive markets 12 April 2021 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today ...
Up to €414 million Exclusive Worldwide Licensing Agreement with Sanofi...
Up to €414 million Exclusive Worldwide Licensing Agreement with Sanofi for C4XD oral IL-17A inhibitor programme C4X Discovery Holdings plc Up to €414 million Exclusive Worldwide Licensing Agreement with Sanofi for C4XD oral IL-17A inhibitor programme €7 million upfront payment in addition to potential pre-clinical milestones of €11 million, clinical and commercial milestones plus royalties Second major licensing deal with a global pharmaceutical company in commercially attractive markets 12 April 2021 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today ...
C4X Discovery and PhoreMost collaboration to accelerate Parkinson’s ...
C4X Discovery and PhoreMost collaboration to accelerate Parkinson’s Disease drug discovery pipeline C4X Discovery Holdings plc (“C4XD”, “C4X Discovery” or the “Company”) C4X Discovery and PhoreMost collaboration to accelerate Parkinson’s Disease drug discovery pipeline 25 June 2019 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today entered into a collaboration with PhoreMost, a UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets. The collaboration, focused initially in Parkinson’s Disease, will combine both company’s te...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.